Negative assessment for InSightec
This article was originally published in The Gray Sheet
Executive Summary
BlueCross BlueShield's Technology Evaluation Center says there is insufficient evidence to conclude that the firm's ExAblate 2000 MR-guided, focused ultrasound system improves net health outcomes of patients with symptomatic uterine fibroids. When the device received PMA approval in October 2004, the firm was required to collect postmarket data for three years (1"The Gray Sheet" Oct. 25, 2004, p. 20)...
You may also be interested in...
InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required
FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.